Wexford Capital’s Outlook Therapeutics OTLK Stock Holding History

Wexford Capital’s Portfolio OTLK Stock Details OTLK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,435	Closed	-$19.2K	–	266
2023 Q4	$19.2K	Buy	+2,435	New	+$20.6K	﹤0.01%	202

Other funds holding OTLK

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Wexford Capital's OTLK Position: Q1 2024 in Review

Wexford Capital sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 2,435 shares — an estimated $19.2K sold.

Wexford Capital first reported a position in OTLK in Q4 2023 and held it in 1 quarter. The position peaked at $19.2K in Q4 2023. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

Wexford Capital reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
Wexford Capital sold 2,435 Outlook Therapeutics shares in Q1 2024, an estimated $19.2K.
Wexford Capital first reported a position in Outlook Therapeutics in Q4 2023 and held it in 1 quarter.
Wexford Capital's Outlook Therapeutics position peaked at $19.2K in Q4 2023.
56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.